Investment Thesis
BiomX is in severe financial distress with negative stockholders equity (-$881K), indicating liabilities exceed assets, coupled with negative operating cash flow (-$5.4M) that cannot service $11.2M in long-term debt. The company appears to have little to no revenue while burning significant cash, leaving approximately 2-3 months of runway at current burn rate.
Strengths
- Minimal capital expenditure ($2K) reduces cash drain from expansion
- Current ratio of 1.24x provides marginal short-term liquidity coverage
- Small asset base ($3.3M) limits downside exposure
Risks
- Negative stockholders equity indicates technical insolvency from balance sheet perspective
- Operating cash flow of -$5.4M with only $1.2M cash creates imminent liquidity crisis within months
- Long-term debt of $11.2M cannot be serviced; negative interest coverage of -1.5x
- Absence of revenue data suggests pre-revenue or failed commercialization
- ROA of -588.7% reflects severe asset inefficiency and value destruction
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Revenue generation or announcement of significant capital infusion
- Restructuring announcements or debt refinancing negotiations
Financial Metrics
Revenue
N/A
Net Income
-19.1M
EPS (Diluted)
$7.38
Free Cash Flow
-5.4M
Total Assets
3.3M
Cash
1.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-588.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.24x
Quick Ratio
1.24x
Debt/Equity
N/A
Debt/Assets
127.1%
Interest Coverage
-1.52x
Long-term Debt
11.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:02:00.176278 |
Data as of: 2026-03-31 |
Powered by Claude AI